Nurix Therapeutics is a biopharmaceutical company that focuses on discovering, developing and commercializing small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels.
Nutrix leverages its extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, to build DELigase, which is an integrated discovery platform for identifying and advancing novel drug candidates targeting E3 ligases, a wide class of enzymes that can modulate proteins within the cell.
Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system, to selectively decrease or increase cellular protein levels.
The wholly owned pipeline of Nutrix comprises of targeted protein degraders of Bruton’s tyrosine kinase, is a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, which is an E3 ligase that regulates T cell activation.
